Systemic treatment in disseminated endometrial cancer.
Both hormonal agents and chemotherapy are of value in the treatment of selected patients with endometrial cancer. In unselected patients with advanced disease about 25% respond to progestational agents and 40% to combination chemotherapy. The choice between the two treatments is made on the basis of a number of prognostic factors, such as receptor status, tumour grade, performance status and tumour burden. Further improvement of treatment outcome is to be expected from new agents such as gonadotrophin releasing hormone analogues, taxol and modulation of 5-fluorouracil.
Neijt
J P
JP
Department of Internal Medicine, Utrecht, The Netherlands.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D045167:Progesterone Congeners / Q000627:therapeutic use; D011980:Receptors, Progesterone / Q000032:analysis
D045167:Progesterone Congeners; D011980:Receptors, Progesterone